Maridebart Cafraglutide
Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple Doses
Amgen · Phase 1 · Not yet recruiting · Enrollment 356
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Maridebart Cafraglutide: SC Presentation 1 | n/r | n/r | n/r | n/r |
| Maridebart Cafraglutide: SC Presentation 2 | n/r | n/r | n/r | n/r |
Not shown
- Maridebart Cafraglutide: SC Presentation 1: endpoint not reported
- Maridebart Cafraglutide: SC Presentation 2: endpoint not reported